The CCSG senior leadership comprises The University of Texas MD Anderson Cancer Center president and principal investigator, Dr. Peter Pisters; vice president for Translational Research and deputy director, Dr. Robert Bast; chief scientific officer ad interim, Dr. Giulio Draetta; associate director, Cancer Prevention and Population Sciences, Dr. Ernie Hawk; associate director, Clinical and Interdisciplinary Research, Dr. George Wilding; associate director, Clinical Research Administration, Dr. Aman Buzdar; associate director, Cancer Health Disparities and Community Outreach, Dr. Lorna McNeill; associate director, Career Enhancement, Dr. Michelle Barton; and associate director, CCSG Administration, Dr. Alan McClelland. As president of MD Anderson, Dr. Pisters has authority over all aspects of the institution, providing vision and ultimate oversight for all clinical, research, education, and prevention activities. The CCSG Executive Committee includes all senior CCSG leaders and is chaired by Dr. Pisters, ensuring alignment between the overall institutional leadership structure and that of the CCSG. MD Anderson uses several external and internal review mechanisms for planning and evaluation to develop and improve the cancer center. Funding from the CCSG supports an External Advisory Board (EAB), consisting of 34 distinguished scientific advisors that meets annually to provide advice to Dr. Pisters, CCSG senior leadership, CCSG program leaders, and CCSG shared resource directors. The EAB reviews research programs and shared resources to 1) evaluate their productivity, excellence, and alignment with institutional goals; 2) identify gaps in scientific expertise or capabilities and suggest options for closing these gaps; 3) consider new programs or restructuring of existing programs; 4) assist in recruiting outstanding faculty to the institution; and 5) evaluate the extent of collaboration among basic scientists, translational/clinical scientists, and population-based investigators, recommending actions to enhance interactivity among these 3 groups. Mechanisms for internal review of research programs, shared resources, and research planning include program retreats; clinical research protocol and concept reviews; presentations by program leaders and shared resource directors to the CCSG Executive Committee and to other leadership groups, including the Community of Chairs meeting of all department chairs; and meetings of center leadership with program leaders. Surveys, focus groups, and user committees have also reviewed each shared resource during the current grant period. As a prelude to updating MD Anderson's Strategic Plan, several Operational Priority task forces have been charged with defining and implementing specific near-term actions of immediate importance to the MD Anderson mission. Although the operational priorities do not represent a strategic plan, the focus on these priorities has established a foundation on which the strategic plan will be developed over the coming year.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Niknam, Sharareh; Barsoumian, Hampartsoum B; Schoenhals, Jonathan E et al. (2018) Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model. Clin Cancer Res 24:5735-5743
Kamal, Mona; Ng, Sweet Ping; Eraj, Salman A et al. (2018) Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncol 79:1-8
Housten, Ashley J; Pappadis, Monique R; Krishnan, Shilpa et al. (2018) Resistance to discontinuing breast cancer screening in older women: A qualitative study. Psychooncology 27:1635-1641
Hsu, Jung-Mao; Xia, Weiya; Hsu, Yi-Hsin et al. (2018) STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun 9:1908
Akay, Catherine L; Albarracin, Constance; Torstenson, Tiffany et al. (2018) Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J 24:28-34
Khong, Hiep; Volmari, Annika; Sharma, Meenu et al. (2018) Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response. J Immunol 200:3464-3474
Candelaria, Rosalind P; Hansakul, Palita; Thompson, Alastair M et al. (2018) Analysis of stereotactic biopsies performed on suspicious calcifications identified within 24 months after completion of breast conserving surgery and radiation therapy for early breast cancer: Can biopsy be obviated? Am J Surg 215:693-698
Kong, Dehan; Ibrahim, Joseph G; Lee, Eunjee et al. (2018) FLCRM: Functional linear cox regression model. Biometrics 74:109-117
Vangapandu, Hima V; Chen, Huiqin; Wierda, William G et al. (2018) Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma 59:1427-1438
Assi, Rita; Kantarjian, Hagop M; Garcia-Manero, Guillermo et al. (2018) A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol 93:277-285

Showing the most recent 10 out of 12418 publications